Palo Alto, CA – Janice Suzann Drew, serving as the Chief of Development Operations for Evommune, Inc. (NASDAQ:EVMN), completed the sale of 20,000 shares of the company's common stock on June 22, 2026. The total transaction value reached $452,600, executed at prices ranging between $22.50 and $23.12 per share, resulting in a weighted average price of $22.63.
This sale was facilitated under a Rule 10b5-1 trading plan, which Ms. Drew established on March 9, 2026. The execution of this transaction aligns with a period of notable stock performance for Evommune. Over the preceding week, the company's shares appreciated by approximately 10%, while the six-month gain stood at 34%.
Before the sale, Ms. Drew acquired the 20,000 shares through the exercise of employee stock options on the same date, June 22, 2026. The acquisition involved 3,839 shares purchased at $3.84 per share and 16,161 shares at $2.99 per share. The total cost for these shares was $63,063, with prices ranging from $2.99 to $3.84. These option exercises were also governed by the aforementioned Rule 10b5-1 trading plan.
Following these transactions, Ms. Drew's direct holdings in Evommune common stock total 67,794 shares. According to InvestingPro analysis, the stock appears overvalued relative to its Fair Value, with the platform providing additional insights through 11 ProTips for investors evaluating the company.
In other recent news, Evommune, Inc. reported its first-quarter financial results, revealing a loss of $0.64 per share. This performance surpassed analyst projections, which had anticipated a loss of $0.76 per share. Additionally, H.C. Wainwright has reiterated its Buy rating on Evommune with a price target of $50. The firm highlighted the completion of enrollment in a Phase 2b trial for chronic spontaneous urticaria, focusing on the efficacy of three different doses of EVO756 compared to a placebo. This trial aims to assess measures such as itch, hive severity, and angioedema, providing crucial data for future Phase 3 trials. These developments are part of Evommune’s ongoing efforts in advancing its clinical programs.